× Medicines Discovery Catapult

Partnering with us opens a wealth of expertise and experience within drug discovery, to help bring your cutting-edge academic research projects to market.

Your ideas, and our understanding of how to translate your academic research projects into commercially viable products and services, will create a winning combination.


The DPFS scheme supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including “repurposing” of existing therapies.

Closes: Wednesday 21st March 2019
Organisation: MRC
Guidelines: Read the full details >

Why partner with the Medicines Discovery Catapult?

  • You’ll receive industry-focused advice and support to enable you to confidently submit a compelling application.
  • Our experienced commercial and scientific teams have connections across industry, academia, finance, government, and research networks – we can help take your projects further towards commercial viability.
  • Our team have a wealth of industrial and academic expertise applied to drug discovery, complex cell models, assay development, biomarker identification, and validation.
  • You’ll have supported access, with specialist expertise, to cutting edge technologies including multi-omics capabilities, mass spec quantitation, mass spec imaging, and organ-on-a-chip capabilities.
  • Our team are experts in translating analytical methodologies that are sensitive, specific, and robust for clinical utility.
  • Our Informatics team have deep expertise in natural language processing, data analysis, machine learning, cheminformatics, and bioinformatics.
  • We can provide access to information not readily available around target validation, drug target interaction, and downstream consequences of engagement.
  • We can help unlock access to appropriately consented patient Samples & Data.
  • We’ll give you access to a network of clinical, academic, and industry experts via Virtual R&D.